Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Using Open-Source Software to Drive Reliability and Security in Lab & Life Sciences

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to bringing new advancements to life. 

Health and Life Science at the Edge’s Morgan Andersen welcomed Intel Product Manager Amy Gilliam and Director of Security Communications Christopher Robinson for a discussion on open-source, everything from what it is, what the culture is like, and managing the quality of the code.

Gilliam says the culture around open source has grown to become a collaborative environment that’s enhanced over the years. Open exchange, de-centralized coding collaboration and peer review are all norms that move open source in a positive direction. “Peer review is a huge part of the open-source development process, in which developers submit code, it gets reviewed by multiple team members and project members before it gets integrated into the main code base by the maintainer,” Gilliam adds. 

From Robinson’s perspective, open source thrives because of the collaboration community. “I’ve been doing security in upstream open source for just under a decade, and I get to work with people from all around the world. We used to have a concept frequently talked about; it was called meritocracy; whereas you were contributing to these communities, people would put forth other ideas, and normally the best idea will win out. After much review and conversation, you’ll generally have better quality code because you’ve had all these different types of inputs.” 

So, how does security factor into open source when privacy is critical to a lot of work done in the health and life science world? Some essential regulations and rules govern the industry to protect human life. Gilliam says technology developers must familiarize themselves with these regulations and ensure the flexibility and capability to meet those compliance requirements now and in the future. 

“The FDA requires disclosures of software submission,” Gilliam said. “So, along with those disclosures of software, are usually calling out of risks and mitigations. Those can be cybersecurity risks, privacy risks, etc. We’re monitoring for that as we’re building software and these analytical tools that will help leverage and accelerate processes in the pharmaceutical industry.” 

Learn more about Open Source solutions by connecting with Amy Gilliam and Christopher Robinson on LinkedIn or visit Intel Health and Life Sciences. 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512